Predictors of Trastuzumab-induced Cardiotoxicity in Breast Cancer Patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210209001

Enrollment

250

Registered

2021-02-09

Start date

2020-10-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer patient Trastuzumab Cardiotoxicity Breast cancer

Interventions

Breast cancer patient treated with trastuzumab

Prevention

Breast cancer patient

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosed with breast cancer with HER-2 positive and treated with Trastuzumab Available of left ventricular function data during trastuzumab therapy

Exclusion criteria

Exclusion criteria: LVEF < 50% before trastuzumab therapy Severe valvular heart disease Prior history of chemotherapy for other cancers

Design outcomes

Primary

Measure	Time frame
Cardiac event 1 year left ventricular ejection fraction	—

Secondary

Measure	Time frame
N/A N/A N/A	—

Countries

Thailand

Contacts

Public ContactNichanan Osataphan

Faculty of Medicine, Chiang Mai University

aom.osataphan@gmail.com66892665663

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026